CHA Biotech signs material transfer deal with Chicago-based CanCure

CHA Biotech signed a material transfer deal with a U.S. biotech company to improve the efficacy of its natural killer cell-based cancer treatment.

The Kosdaq-listed biotech on Monday will bring in an antibody developed by CanCure, a Chicago-based immunotherapy drug developer, which targets a specific antigen expressed by cancer cells and can potentially help natural killer cells kill tumor cells.

CHA Biotech said that it will work with CanCure in order to increase the activity of natural killer cells and improve anti-cancer treatment efficacy using the U.S. company’s antibody substances.

“We are looking for various types of combination treatments with cancer immunotherapies and antibody drugs to expand and strengthen our natural killer cell treatment pipelines,” CHA Biotech CEO Lee Hyun-jung said.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]